Please enable JavaScript to continue using this application.

Compare $ABEO vs $IKT | Chartloom

Compare

$ABEO vs $IKT

Abeona Therapeutics Inc · Inhibikase Therapeutics Inc

ABEO

Abeona Therapeutics Inc

IKT

Inhibikase Therapeutics Inc

Compare $ABEO vs $IKT

Comparing Abeona Therapeutics Inc and Inhibikase Therapeutics Inc

ABEOAbeona Therapeutics Inc

IKTInhibikase Therapeutics Inc

ABEOAbeona Therapeutics Inc

Market cap

$282M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

3.20x

Rev growth (TTM)

6280.0%

YTD performance

-7.0%

52W performance

-10.8%

FCF yield

-29.0%

IKTInhibikase Therapeutics Inc

Market cap

$309M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

1.0%

52W performance

18.7%

FCF yield

-13.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ABEO

IKT

Detailed metrics comparison

ABEO

Abeona Therapeutics Inc

IKT

Inhibikase Therapeutics Inc

Market Cap

ABEO$282M

IKT$309M

Enterprise Value

ABEO$240M

IKT$278M

Price

ABEO$4.94

IKT$1.97

P/E Ratio

ABEON/A

IKTN/A

P/S Ratio

ABEO11.03x

IKT872.10x

EV/Sales

ABEO9.42x

IKT774.58x

EV/EBITDA

ABEO3.95x

IKT0.00x

P/B Ratio

ABEO2.25x

IKT1.82x

P/FCF Ratio

ABEON/A

IKTN/A

EV/FCF

ABEO-2.95x

IKT-6.53x

PEG Ratio

ABEON/A

IKTN/A

Forward P/E (NTM)

ABEON/A

IKTN/A

Forward P/S (NTM)

ABEO3.20x

IKTN/A

Revenue (TTM)

ABEO$26M

IKT$0

Revenue Growth (YoY)

ABEO6280.0%

IKTN/A

Forward Rev Growth

ABEO131.0%

IKT0.0%

Gross Margin (TTM)

ABEO67.1%

IKT0.0%

Operating Margin (TTM)

ABEO0.0%

IKT0.0%

EBITDA Margin (TTM)

ABEO-316.6%

IKT0.0%

Net Margin (TTM)

ABEO-246.4%

IKT0.0%

FCF Margin (TTM)

ABEO-319.5%

IKTN/A

Net Income (TTM)

ABEO$-63M

IKT$-44M

FCF (TTM)

ABEO$-82M

IKT$-43M

EPS (TTM)

ABEO-$1.10

IKT-$0.25

ROE (TTM)

ABEO-4169.0%

IKT-4690.0%

ROA (TTM)

ABEO-3036.0%

IKT-4348.0%

ROIC (TTM)

ABEO-3719.0%

IKT-4690.0%

Cash

ABEO$56M

IKT$31M

Debt

ABEO$15M

IKT$0

Net Cash/Debt

ABEO$41M

IKT$31M

Current Ratio (TTM)

ABEO6.63x

IKT15.82x

Quick Ratio (TTM)

ABEO6.32x

IKT15.50x

Debt/Equity (TTM)

ABEO0.12x

IKT0.00x

Debt/Assets (TTM)

ABEO0.0%

IKT0.0%

Interest Coverage (TTM)

ABEON/A

IKTN/A

Net Debt/EBITDA (TTM)

ABEO0.00x

IKT0.00x

Beta

ABEO1.45

IKT0.92

52W Performance

ABEO-10.8%

IKT18.7%

YTD Performance

ABEO-7.0%

IKT1.0%

% from 52W High

ABEO-35.4%

IKT-24.5%

% from 52W Low

ABEO23.5%

IKT48.1%

Asset Turnover (TTM)

ABEO0.13x

IKT0.01x

FCF Yield (TTM)

ABEO-29.0%

IKT-13.8%

Earnings Yield (TTM)

ABEO-22.3%

IKT-14.3%

Dividend Yield (TTM)

ABEON/A

IKTN/A

Rule of 40

ABEO5,960.5

IKT0.0

EV/GP/RG

ABEO0.04

IKTN/A

Ticker research

View ABEO research View IKT research

Metric	ABEO Abeona Therapeutics Inc	IKT Inhibikase Therapeutics Inc
Market & Valuation
Market Cap	$282M	$309M
Enterprise Value	$240M	$278M
Price	$4.94	$1.97
P/E Ratio	N/A	N/A
P/S Ratio	11.03x	872.10x
EV/Sales	9.42x	774.58x
EV/EBITDA	3.95x	0.00x
P/B Ratio	2.25x	1.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.95x	-6.53x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.20x	N/A
Revenue & Growth
Revenue (TTM)	$26M	$0
Revenue Growth (YoY)	6280.0%	N/A
Forward Rev Growth	131.0%	0.0%
Profitability
Gross Margin (TTM)	67.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-316.6%	0.0%
Net Margin (TTM)	-246.4%	0.0%
FCF Margin (TTM)	-319.5%	N/A
Net Income (TTM)	$-63M	$-44M
FCF (TTM)	$-82M	$-43M
EPS (TTM)	-$1.10	-$0.25
ROE (TTM)	-4169.0%	-4690.0%
ROA (TTM)	-3036.0%	-4348.0%
ROIC (TTM)	-3719.0%	-4690.0%
Financial Health
Cash	$56M	$31M
Debt	$15M	$0
Net Cash/Debt	$41M	$31M
Current Ratio (TTM)	6.63x	15.82x
Quick Ratio (TTM)	6.32x	15.50x
Debt/Equity (TTM)	0.12x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.45	0.92
52W Performance	-10.8%	18.7%
YTD Performance	-7.0%	1.0%
% from 52W High	-35.4%	-24.5%
% from 52W Low	23.5%	48.1%
Efficiency & Yields
Asset Turnover (TTM)	0.13x	0.01x
FCF Yield (TTM)	-29.0%	-13.8%
Earnings Yield (TTM)	-22.3%	-14.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	5,960.5	0.0
EV/GP/RG	0.04	N/A
Ticker research	View ABEO research	View IKT research

Valuation

P/S Ratio

ABEO

11.03x

IKT

872.10x

EV/FCF

IKT

-6.53x

ABEO

-2.95x

Growth & revenue

Revenue Growth TTM

ABEO

6280.0%

Forward Revenue Growth

ABEO

131.0%

IKT

0.0%

Profitability & performance

Gross Margin

ABEO

67.1%

IKT

0.0%

ROE

ABEO

-4169.0%

IKT

-4690.0%

FCF Yield %

IKT

-13.8%

ABEO

-29.0%

52-Week Performance

IKT

18.7%

ABEO

-10.8%

Detailed metrics comparison

ABEO

Abeona Therapeutics Inc

IKT

Inhibikase Therapeutics Inc

Market Cap

ABEO$282M

IKT$309M

Enterprise Value

ABEO$240M

IKT$278M

Price

ABEO$4.94

IKT$1.97

P/E Ratio

ABEON/A

IKTN/A

P/S Ratio

ABEO11.03x

IKT872.10x

EV/Sales

ABEO9.42x

IKT774.58x

EV/EBITDA

ABEO3.95x

IKT0.00x

P/B Ratio

ABEO2.25x

IKT1.82x

P/FCF Ratio

ABEON/A

IKTN/A

EV/FCF

ABEO-2.95x

IKT-6.53x

PEG Ratio

ABEON/A

IKTN/A

Forward P/E (NTM)

ABEON/A

IKTN/A

Forward P/S (NTM)

ABEO3.20x

IKTN/A

Revenue (TTM)

ABEO$26M

IKT$0

Revenue Growth (YoY)

ABEO6280.0%

IKTN/A

Forward Rev Growth

ABEO131.0%

IKT0.0%

Gross Margin (TTM)

ABEO67.1%

IKT0.0%

Operating Margin (TTM)

ABEO0.0%

IKT0.0%

EBITDA Margin (TTM)

ABEO-316.6%

IKT0.0%

Net Margin (TTM)

ABEO-246.4%

IKT0.0%

FCF Margin (TTM)

ABEO-319.5%

IKTN/A

Net Income (TTM)

ABEO$-63M

IKT$-44M

FCF (TTM)

ABEO$-82M

IKT$-43M

EPS (TTM)

ABEO-$1.10

IKT-$0.25

ROE (TTM)

ABEO-4169.0%

IKT-4690.0%

ROA (TTM)

ABEO-3036.0%

IKT-4348.0%

ROIC (TTM)

ABEO-3719.0%

IKT-4690.0%

Cash

ABEO$56M

IKT$31M

Debt

ABEO$15M

IKT$0

Net Cash/Debt

ABEO$41M

IKT$31M

Current Ratio (TTM)

ABEO6.63x

IKT15.82x

Quick Ratio (TTM)

ABEO6.32x

IKT15.50x

Debt/Equity (TTM)

ABEO0.12x

IKT0.00x

Debt/Assets (TTM)

ABEO0.0%

IKT0.0%

Interest Coverage (TTM)

ABEON/A

IKTN/A

Net Debt/EBITDA (TTM)

ABEO0.00x

IKT0.00x

Beta

ABEO1.45

IKT0.92

52W Performance

ABEO-10.8%

IKT18.7%

YTD Performance

ABEO-7.0%

IKT1.0%

% from 52W High

ABEO-35.4%

IKT-24.5%

% from 52W Low

ABEO23.5%

IKT48.1%

Asset Turnover (TTM)

ABEO0.13x

IKT0.01x

FCF Yield (TTM)

ABEO-29.0%

IKT-13.8%

Earnings Yield (TTM)

ABEO-22.3%

IKT-14.3%

Dividend Yield (TTM)

ABEON/A

IKTN/A

Rule of 40

ABEO5,960.5

IKT0.0

EV/GP/RG

ABEO0.04

IKTN/A

Ticker research

View ABEO research View IKT research

Metric	ABEO Abeona Therapeutics Inc	IKT Inhibikase Therapeutics Inc
Market & Valuation
Market Cap	$282M	$309M
Enterprise Value	$240M	$278M
Price	$4.94	$1.97
P/E Ratio	N/A	N/A
P/S Ratio	11.03x	872.10x
EV/Sales	9.42x	774.58x
EV/EBITDA	3.95x	0.00x
P/B Ratio	2.25x	1.82x
P/FCF Ratio	N/A	N/A
EV/FCF	-2.95x	-6.53x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	3.20x	N/A
Revenue & Growth
Revenue (TTM)	$26M	$0
Revenue Growth (YoY)	6280.0%	N/A
Forward Rev Growth	131.0%	0.0%
Profitability
Gross Margin (TTM)	67.1%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-316.6%	0.0%
Net Margin (TTM)	-246.4%	0.0%
FCF Margin (TTM)	-319.5%	N/A
Net Income (TTM)	$-63M	$-44M
FCF (TTM)	$-82M	$-43M
EPS (TTM)	-$1.10	-$0.25
ROE (TTM)	-4169.0%	-4690.0%
ROA (TTM)	-3036.0%	-4348.0%
ROIC (TTM)	-3719.0%	-4690.0%
Financial Health
Cash	$56M	$31M
Debt	$15M	$0
Net Cash/Debt	$41M	$31M
Current Ratio (TTM)	6.63x	15.82x
Quick Ratio (TTM)	6.32x	15.50x
Debt/Equity (TTM)	0.12x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.45	0.92
52W Performance	-10.8%	18.7%
YTD Performance	-7.0%	1.0%
% from 52W High	-35.4%	-24.5%
% from 52W Low	23.5%	48.1%
Efficiency & Yields
Asset Turnover (TTM)	0.13x	0.01x
FCF Yield (TTM)	-29.0%	-13.8%
Earnings Yield (TTM)	-22.3%	-14.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	5,960.5	0.0
EV/GP/RG	0.04	N/A
Ticker research	View ABEO research	View IKT research